Organization
Vega Therapeutics
1 clinical trial
Clinical trial
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of VGA039 Following IV or SC Administration of Single Ascending Doses in Healthy Adults and Subcutaneous Adult Patients With Von Willebrand DiseaseStatus: Recruiting, Estimated PCD: 2024-11-01